日光性荨麻疹：机制研究和治疗现状与展望

doi:10.35541/cjd.20250682

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (7): 619-625.doi: 10.35541/cjd.20250682

• 专家论坛·光皮肤病学 • 上一篇下一篇

日光性荨麻疹：机制研究和治疗现状与展望

陈荃¹ 何凤梅^1，2 周欣¹ 梁碧华¹ 朱慧兰¹

¹广州市皮肤病医院广州医科大学皮肤病研究所，广州 510095；²广州医科大学，广州 511436

收稿日期:2025-12-03 修回日期:2026-06-04 发布日期:2026-07-03
通讯作者: 陈荃 E-mail:quanchen1985@gmail.com
基金资助:
广州市科技计划项目（2023A03J0942，2023A03J0943）

Solar urticaria: pathogenesis, current treatments, and future prospects

Chen Quan¹, He Fengmei^1,2, Zhou Xin¹, Liang Bihua¹, Zhu Huilan¹

¹Guangzhou Dermatology Hospital, Institute of Dermatology, Guangzhou Medical University, Guangzhou 510095, China; ²Guangzhou Medical University, Guangzhou 511436, China

Received:2025-12-03 Revised:2026-06-04 Published:2026-07-03
Contact: Chen Quan E-mail:quanchen1985@gmail.com
Supported by:
Guangzhou Science and Technology Plan Project（2023A03J0942，2023A03J0943）

摘要/Abstract

摘要： 【摘要】日光性荨麻疹（SU）是一种由紫外线和/或可见光辐射诱发的罕见光敏性皮肤病。SU的病理机制有待进一步阐明，主要涉及血清和/或真皮内发色团吸收作用光谱的光线后转化为光变应原，诱导肥大细胞活化，出现风团、红斑、偶见血管性水肿等临床表现。该病机制涉及异常发色基团和IgE，肥大细胞是主要的效应细胞，通过IgE-高亲和力IgE抗体Fc段的I型受体介导的信号通路、信号转导子及转录激活子3通路、Opsin非经典通路等影响疾病发生发展。SU的临床管理方案主要包括防晒避光、抗组胺药物治疗、生物制剂治疗、光硬化治疗等。本文结合国内外研究现状，就SU的发病机制和治疗进展进行阐述。

关键词: 荨麻疹, 日光性荨麻疹, 紫外线, 可见光, 肥大细胞, IgE, 奥马珠单抗

Abstract: 【Abstract】 Solar urticaria （SU） is a rare photosensitive skin disorder induced by ultraviolet and/or visible light radiation. Its pathological mechanisms remain unclear, primarily involving the conversion of serum and/or dermal chromophores into photoallergens after absorbing specific action spectra, subsequently inducing mast cell activation and leading to clinical manifestations such as wheals, erythema, and occasionally angioedema. The pathogenesis of SU involves abnormal chromophores and IgE, with mast cells serving as the primary effector cells. Its occurrence and development are mediated by the IgE-FcεRⅠ signaling pathway, the signal transducer and activator of transcription 3 pathway, and the non-classical opsin pathway. Clinical management strategies for SU mainly include sun protection and light avoidance, antihistamines, biologics, and photohardening therapy. This article reviews advances in the pathogenesis and treatment of SU based on current research in China and other countries.

Key words: Urticaria, Solar urticaria, Ultraviolet, Visible light, Mast cell, IgE, Omalizumab

陈荃何凤梅周欣梁碧华朱慧兰. 日光性荨麻疹：机制研究和治疗现状与展望[J]. 中华皮肤科杂志, 2026,59(7):619-625. doi:10.35541/cjd.20250682

Chen Quan, He Fengmei, Zhou Xin, Liang Bihua, Zhu Huilan. Solar urticaria: pathogenesis, current treatments, and future prospects[J]. Chinese Journal of Dermatology, 2026, 59(7): 619-625.doi:10.35541/cjd.20250682

参考文献 63

［1］	McSweeney SM, Christou E, Maurer M, et al. Physical urticaria: clinical features, pathogenesis, diagnostic work⁃up, and management［J］. J Am Acad Dermatol, 2023,89（2）:324⁃337. DOI: 10.1016/j.jaad.2023.02.062.
［2］	Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. DOI: 10.1111/ddg.14309.
［3］	Hamel R, Mohammad TF, Chahine A, et al. Comparison of racial distribution of photodermatoses in USA academic dermatology clinics: a multicenter retrospective analysis of 1080 patients over a 10⁃year period［J］. Photodermatol Photoimmunol Photomed, 2020,36（3）:233⁃240. DOI: 10.1111/phpp.12543.
［4］	Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children［J］. Photodermatol Photoimmunol Photomed, 2018,34（4）:262⁃268. DOI: 10.1111/phpp.12385.
［5］	Berberi G, Maazi M, Prosty C, et al. Health⁃related quality of life in chronic urticaria: a systematic review and Meta⁃analysis［J］. J Allergy Clin Immunol Pract, 2025,13（9）:2317⁃2328. DOI: 10.1016/j.jaip.2025.03.049.
［6］	Rutter KJ, Ashraf I, Cordingley L, et al. Quality of life and psychological impact in the photodermatoses: a systematic review［J］. Br J Dermatol, 2020,182（5）:1092⁃1102. DOI: 10.1111/bjd.18326.
［7］	Thumber NK, Elsbahi H, McGrath C, et al. Characterization of the clinical and photobiologic features of solar urticaria: a UK multicentre cross⁃sectional study［J］. Br J Dermatol, 2025,193（5）:1001⁃1003. DOI: 10.1093/bjd/ljaf159.
［8］	Pérez⁃Ferriols A, Barnadas M, Gardeazábal J, et al. Solar urticaria: epidemiology and clinical phenotypes in a Spanish series of 224 patients［J］. Actas Dermosifiliogr, 2017,108（2）:132⁃139. DOI: 10.1016/j.ad.2016.09.003.
［9］	Sridhar B, Lokesh L. The Impact of solar urticaria on psychological well⁃being and perceived social support［J］.Int J Health Sci Res, 2024,14（4）:119⁃128. DOI: 10.52403/ijhsr. 20240418.
［10］	Harber LC, Holloway RM, Wheatley VR, et al. Immunologic and biophysical studies in solar urticaria［J］. J Invest Dermatol, 1963,41:439⁃443. DOI: 10.1038/jid.1963.138.
［11］	Leenutaphong V, Hölzle E, Plewig G. Pathogenesis and classification of solar urticaria: a new concept［J］. J Am Acad Dermatol, 1989,21（2 Pt 1）:237⁃240. DOI: 10.1016/s0190⁃9622（89）70167⁃5.
［12］	McSweeney SM, Sarkany R, Fassihi H, et al. Pathogenesis of solar urticaria: classic perspectives and emerging concepts［J］. Exp Dermatol, 2022,31（4）:586⁃593. DOI: 10.1111/exd.14493.
［13］	中华医学会皮肤性病学分会免疫学组. 中国慢性诱导性荨麻疹诊治专家共识（2023）［J］. 中华皮肤科杂志, 2023,56（6）:479⁃488. DOI: 10.35541/cjd.20220819.
［14］	Reolid A, Muñoz⁃Aceituno E, Rodríguez⁃Jiménez P, et al. Delayed⁃onset solar urticaria coexisting with spontaneous chronic urticaria and polymorphic light eruption［J］. Actas Dermosifiliogr, 2022,113（10）:978⁃979. DOI: 10.1016/j.ad. 2022.01.045.
［15］	de Gálvez MV, Aguilera J, López N, et al. Delayed⁃onset solar urticaria with generalized wheals caused by UVB associated with polymorphic light eruption caused by UVA［J］. Photodermatol Photoimmunol Photomed, 2015,31（2）:107⁃110. DOI: 10.1111/phpp.12144.
［16］	Uetsu N, Murata C, Okamoto H. Childhood fixed solar urticaria induced by visible light［J］. Photodermatol Photoimmunol Photomed, 2023,39（2）:159⁃161. DOI: 10.1111/phpp.12850.
［17］	Wessendorf U, Hanneken S, Haust M, et al. Fixed solar urticaria with delayed onset［J］. J Am Acad Dermatol, 2009,60（4）:695⁃697. DOI: 10.1016/j.jaad.2008.08.044.
［18］	Charansol A, Bourdenet V, Hanniet A, et al. Infrared radiation⁃induced urticaria: a case report［J］. Contact Dermatitis, 2025,93（3）:269⁃270. DOI: 10.1111/cod.14826.
［19］	de Gálvez MV, Aguilera J, Sánchez⁃Roldán C, et al. Infrared radiation increases skin damage induced by other wavelengths in solar urticaria［J］. Photodermatol Photoimmunol Photomed, 2016,32（5⁃6）:284⁃290. DOI: 10.1111/phpp.12270.
［20］	Chong WS, Khoo SW. Solar urticaria in Singapore: an uncommon photodermatosis seen in a tertiary dermatology center over a 10⁃year period［J］. Photodermatol Photoimmunol Photomed, 2004,20（2）:101⁃104. DOI: 10.1111/j.1600⁃0781.2004.00083.x.
［21］	Imamura S, Oda Y, Fukumoto T, et al. Solar urticaria: clinical characteristics, treatment effectiveness, long⁃term prognosis, and QOL status in 29 patients［J］. Front Med （Lausanne）, 2024,11:1328765. DOI: 10.3389/fmed.2024.1328765.
［22］	Uetsu N, Nomura Y, Matsuyama Y, et al. Characteristics and clinical significance of augmentation spectra in solar urticaria［J］. J Dermatol, 2020,47（4）:369⁃377. DOI: 10.1111/1346⁃8138.15234.
［23］	Uetsu N, Miyauchi⁃Hashimoto H, Okamoto H, et al. The clinical and photobiological characteristics of solar urticaria in 40 patients［J］. Br J Dermatol, 2000,142（1）:32⁃38. DOI: 10.1046/j.1365⁃2133.2000.03238.x.
［24］	陈国梁, 闫春林, 廖康煌. 12例日光性荨麻疹的临床及光生物学特征［J］. 中华皮肤科杂志, 2002,35（1）:53.
［25］	董碧麟, 夏凡, 闫鸣, 等. 光激发试验确诊日光性荨麻疹一例［J］. 中华皮肤科杂志, 2008,（4）:213. DOI: 10.3321/j.issn:0412⁃4030.2008.04.018.
［26］	冉德琳, 赵伟, 王广进. 日光性荨麻疹二例并文献复习［J］. 中国麻风皮肤病杂志, 2024,40（6）:438⁃440. DOI: 10.12144/zgmfskin202406438.
［27］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. DOI: 10.1111/all.12884.
［28］	Muñoz M, Kiefer LA, Pereira MP, et al. New insights into chronic inducible urticaria［J］. Curr Allergy Asthma Rep, 2024,24（8）:457⁃469. DOI: 10.1007/s11882⁃024⁃01160⁃y.
［29］	Rantanen T, Suhonen R. Solar urticaria: a case with increased skin mast cells and good therapeutic response to an antihistamine［J］. Acta Derm Venereol, 1980,60（4）:363⁃365.
［30］	Baart de la Faille H, Rottier PB, Baart de la Faille⁃Kuyper EH. Solar urticaria. A case with possible increase of skin mast cells［J］. Br J Dermatol, 1975,92（1）:101⁃107. DOI: 10.1159/0001 44432.
［31］	Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: effects, mechanisms and relevance for skin diseases［J］. Exp Dermatol, 2018,27（1）:3⁃8. DOI: 10.1111/exd.13402.
［32］	Rutter KJ, Peake M, Hawkshaw NJ, et al. Solar urticaria involves rapid mast cell STAT3 activation and neutrophil recruitment, with FcεRI as an upstream regulator［J］. J Allergy Clin Immunol, 2024,153（5）:1369⁃1380.e15. DOI: 10.1016/j.jaci. 2023.12.021.
［33］	Yamamoto H, Kiryu M, Sawaguchi Y, et al. Opsin 3⁃mediated regulation of blue light⁃induced β⁃hexosaminidase release from mast cells［J］. Drug Discov Ther, 2025,19（3）:184⁃188. DOI: 10.5582/ddt.2025.01035.
［34］	Yip KH, Kolesnikoff N, Yu C, et al. Mechanisms of vitamin D₃ metabolite repression of IgE⁃dependent mast cell activation［J］. J Allergy Clin Immunol, 2014,133（5）:1356⁃1364, 1364.e1⁃14. DOI: 10.1016/j.jaci.2013.11.030.
［35］	Oda Y, Washio K, Fukunaga A, et al. Establishment of the basophil activation test to detect photoallergens in solar urticaria［J］. J Allergy Clin Immunol Pract, 2020,8（8）:2817⁃2819.e1. DOI: 10.1016/j.jaip.2020.04.042.
［36］	Patra V, Gallais Sérézal I, Wolf P. Potential of skin microbiome, pro⁃ and/or pre⁃biotics to affect local cutaneous responses to UV exposure［J］. Nutrients, 2020,12（6）:1795. DOI: 10.3390/nu120 61795.
［37］	Gour N, Dong X. The MRGPR family of receptors in immunity［J］. Immunity, 2024,57（1）:28⁃39. DOI: 10.1016/j.immuni. 2023.12.012.
［38］	Engler Markowitz M, Noyman Y, Khanimov I, et al. Efficacy of therapies for solar urticaria: a systematic review and meta⁃analysis［J］. J Clin Med, 2025,14（16）:5736. DOI: 10.3390/jcm14165736.
［39］	Exposito⁃Serrano V, Curto⁃Barredo L, Aguilera Peiro P, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients［J］. Br J Dermatol, 2021,184（1）:167⁃168. DOI: 10.1111/bjd.19425.
［40］	Soegiharto R, Alizadeh Aghdam M, Sørensen JA, et al. Omalizumab is effective and safe in chronic inducible urticaria （CIndU）: real⁃world data from a large multi⁃national UCARE study［J］. Allergy, 2025,80（2）:489⁃499. DOI: 10.1111/all. 16334.
［41］	Alawadhi JF, Ayer J. Efficacy of monoclonal antibodies and Janus kinase inhibitors in the treatment of idiopathic photosensitive skin disorders: a systematic review［J］. Clin Exp Dermatol, 2026,51（4）:548⁃554. DOI: 10.1093/ced/llaf487.
［42］	Morgado⁃Carrasco D, Fustà⁃Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature［J］. Photodermatol Photoimmunol Photomed, 2018,34（3）:194⁃199. DOI: 10.1111/phpp.12370.
［43］	Iannelli M, Passanisi S, Crisafulli G, et al. Long term treatment with omalizumab in adolescent with refractory solar urticaria［J］. Ital J Pediatr, 2021,47（1）:195. DOI: 10.1186/s13052⁃021⁃01151⁃z.
［44］	曲芃, 杜东红, 杨宝琦. 奥马珠单抗治疗儿童日光性荨麻疹一例并文献复习［J］. 中国麻风皮肤病杂志, 2024,40（2）:116⁃117. DOI: 10.12144/zgmfskin202402116.
［45］	Hershkovitz Y, Khanimov I, Rubin L, et al. Successful ligelizumab treatment of severe refractory solar urticaria［J］. J Allergy Clin Immunol Pract, 2023,11（8）:2576⁃2577. DOI: 10.1016/j.jaip.2023.01.052.
［46］	Navarro⁃Triviño FJ, Prados⁃Carmona A, Aguilera J, et al. Treatment of refractory solar urticaria: could dupilumab fill the current gap?［J］. J Dtsch Dermatol Ges, 2023,21（6）:652⁃653. DOI: 10.1111/ddg.15025.
［47］	Matsuda M, Nakajima K, Aoki N, et al. A case of solar urticaria complicated by eosinophilic granulomatosis with polyangiitis treated with mepolizumab［J］. J Dermatol, 2025,52（3）:e225⁃e226. DOI: 10.1111/1346⁃8138.17479.
［48］	Sher M, Mimouni D, Levi A. Solar urticaria successfully treated with remibrutinib［J/OL］. J Allergy Clin Immunol Pract, 2026（2026⁃05⁃21）［2026⁃06⁃03］. https://www.sciencedirect.com/science/article/pii/S2213219826004162?via%3Dihub. DOI: 10.1016/j.jaip.2026.05.012.［published online ahead of print］.
［49］	Wu J, Cotliar R. Afamelanotide: an orphan drug with potential for broad dermatologic applications［J］. J Drugs Dermatol, 2021,20（3）:290⁃294. DOI: 10.36849/JDD.5526.
［50］	Caccialanza M, Recalcati S, Piccinno R. Oral polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatoses［J］. G Ital Dermatol Venereol, 2011,146（2）:85⁃87.
［51］	Hurabielle C, Bedane C, Avenel⁃Audran M, et al. No major effect of cyclosporin A in patients with severe solar urticaria: a french retrospective case series［J］. Acta Derm Venereol, 2015,95（8）:1030⁃1031. DOI: 10.2340/00015555⁃2140.
［52］	Ensina LF, Brandão L, Netchiporouk E, et al. Managing chronic urticaria in children: an update［J］. Curr Allergy Asthma Rep, 2025,25（1）:21. DOI: 10.1007/s11882⁃025⁃01202⁃z.
［53］	杨雅琪, 蒋鑫, 常锦绣, 等. 特发性光线性皮肤病的光硬化治疗［J］. 中华皮肤科杂志, 2023,56（12）:1091⁃1095. DOI: 10. 35541/cjd.20230347.
［54］	Jiang AJ, Lim HW. Phototherapy in the evaluation and management of photodermatoses［J］. Dermatol Clin, 2020,38（1）:71⁃77. DOI: 10.1016/j.det.2019.08.007.
［55］	Masuoka E, Fukunaga A, Kishigami K, et al. Successful and long⁃lasting treatment of solar urticaria with ultraviolet A rush hardening therapy［J］. Br J Dermatol, 2012,167（1）:198⁃201. DOI: 10.1111/j.1365⁃2133.2012.10944.x.
［56］	Mori N, Makino T, Matsui K, et al. Successful treatment with UVA rush hardening in a case of solar urticaria［J］. Eur J Dermatol, 2014,24（1）:117⁃119. DOI: 10.1684/ejd.2013.2238.
［57］	Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria［J］. J Am Acad Dermatol, 2000,42（6）:1030⁃1032. DOI: 10.1016/s0190⁃9622（00）90299⁃8.
［58］	Calzavara⁃Pinton P, Zane C, Rossi M, et al. Narrowband ultraviolet B phototherapy is a suitable treatment option for solar urticaria［J］. J Am Acad Dermatol, 2012,67（1）:e5⁃e9. DOI: 10.1016/j.jaad.2011.01.030.
［59］	Chicharro P, Rodríguez⁃Jiménez P, Capusan TM, et al. Induction of light tolerance using narrowband UV⁃B in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:888⁃892. DOI: 10.1016/j.ad.2018.06.005.
［60］	Aubin F, Porcher R, Jeanmougin M, et al. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phaseⅡ multicenter study［J］. J Am Acad Dermatol, 2014,71（5）:948⁃953.e1. DOI: 10.1016/j.jaad.2014.07.023.
［61］	Adamski H, Bedane C, Bonnevalle A, et al. Solar urticaria treated with intravenous immunoglobulins［J］. J Am Acad Dermatol, 2011,65（2）:336⁃340. DOI: 10.1016/j.jaad.2010.05. 040.
［62］	Boontaveeyuwat E, Willis F, Fassihi H, et al. Successful serial plasmapheresis for solar urticaria, a case report and literature review［J］. J Dermatolog Treat, 2024,35（1）:2350229. DOI: 10.1080/09546634.2024.2350229.
［63］	Mang R, Stege H, Budde MA, et al. Successful treatment of solar urticaria by extracorporeal photochemotherapy （photopheresis）⁃⁃a case report［J］. Photodermatol Photoimmunol Photomed, 2002,18（4）:196⁃198. DOI: 10.1034/j.1600⁃0781.2002.00683.x.

[1]	宇文天翊周子桢田竞宇陈思涵李敏张峰源顾恒陈旭. 角质形成细胞谷氨酰胺酶1/氨代谢轴在中波紫外线诱导的急性损伤和银屑病皮肤炎症中的表达研究[J]. 中华皮肤科杂志, 2026, 59(7): 654-661.
[2]	胡煜鲁严陈崑顾恒. [开放获取] 规范化、精准化与全周期管理：《白癜风患者家庭光疗管理规范》解读[J]. 中华皮肤科杂志, 2026, 59(7): 632-636.
[3]	中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 595-610.
[4]	王彩霞徐凡石晶朱海莲卢桂玲王红梅. 奥马珠单抗和度普利尤单抗治疗大疱性类天疱疮的疗效和安全性系统综述[J]. 中华皮肤科杂志, 2026, 59(3): 262-268.
[5]	艾芳婷姚春霞苗国英孙紫君张丽. 钙敏感受体介导中波紫外线照射致角质形成细胞铁死亡的研究[J]. 中华皮肤科杂志, 2026, 59(1): 36-43.
[6]	古丽孜巴·图尔荪赵亚楠王红娟康晓静屈园园. [开放获取] 自体细胞移植联合不同递增剂量的308nm SQ LED光治疗难治性稳定期白癜风的临床疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 852-856.
[7]	宋璞刘宇郭森李舒丽刘玲李春英. 肥大细胞来源的趋化因子配体5影响氧化应激状态下白癜风CD8+ T细胞的迁移[J]. 中华皮肤科杂志, 2025, 58(9): 839-843.
[8]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838.
[9]	沈雨晴宋秀祖. 紫外线与雄激素性秃发[J]. 中华皮肤科杂志, 2025, 58(7): 676-678.
[10]	郑雅萱苏惠春. 汗液在胆碱能性荨麻疹中的作用[J]. 中华皮肤科杂志, 2025, 58(6): 573-577.
[11]	李恩泽陈璐张楚翘姚昱旭焦晴晴季江. 肠道菌群及短链脂肪酸与慢性自发性荨麻疹相关性研究进展[J]. 中华皮肤科杂志, 2025, 58(6): 577-581.
[12]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 中国难治性慢性自发性荨麻疹诊治指南（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 485-496.
[13]	唐汇洋杨芷样希姚正秋陈邦涛郝飞. 氧化三甲胺参与慢性自发性荨麻疹发病的机制研究[J]. 中华皮肤科杂志, 2025, 58(6): 515-522.
[14]	黄雪薇陈奇权杨显杰陈安祺王欢邓思思翟志芳王娟宋志强. 荨麻疹性血管炎与伴色素沉着慢性自发性荨麻疹的临床与病理特征对比分析[J]. 中华皮肤科杂志, 2025, 58(6): 508-514.
[15]	肖萌赵美茹张新美张俊艳亓玉青王惠平. 慢性自发性荨麻疹患者疾病负担的单中心回顾性分析[J]. 中华皮肤科杂志, 2025, 58(6): 530-535.

日光性荨麻疹：机制研究和治疗现状与展望

Solar urticaria: pathogenesis, current treatments, and future prospects

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 63

相关文章 15

Metrics

本文评价

推荐阅读 10